


Organic & Biomolecular Chemistry

www.rsc.org/obc



ISSN 1477-0520



PAPER

Jacek Jemielity *et al.*

Cap analogs containing 6-thioguanosine – reagents for the synthesis of mRNAs selectively photo-crosslinkable with cap-binding biomolecules

Cap analogs containing 6-thioguanosine – reagents for the synthesis of mRNAs selectively photo-crosslinkable with cap-binding biomolecules†

Cite this: *Org. Biomol. Chem.*, 2014, **12**, 4841

Monika Nowakowska,^{‡a} Joanna Kowalska,^{‡a} Franck Martin,^b Arnaud d'Orchymont,^b Joanna Zuberek,^a Maciej Lukaszewicz,^a Edward Darzynkiewicz^{a,c} and Jacek Jemielity^{*a,c}

Numerous biomolecules recognize the 7-methylguanosine cap structure present at the 5' ends of eukaryotic mRNAs. Photo-crosslinking is a valuable technique to study these interactions. We report three anti-reverse cap analogs containing a photo-activable nucleoside, 6-thioguanosine (^{6S}G), that enable the synthesis of capped RNAs with ^{6S}G positioned exclusively as the first transcribed nucleotide. The effect of the 6-thioguanosine moiety on binding to the translation factor eIF4E and the efficiency of mRNA translation was determined. The utility of mRNAs with a ^{6S}G-modified cap in crosslinking experiments is shown by mapping the histone H4 cap-binding pocket.

Received 8th January 2014,
Accepted 26th March 2014

DOI: 10.1039/c4ob00059e

www.rsc.org/obc

Introduction

Various biomacromolecules are capable of binding to the 7-methylguanosine triphosphate cap structure present at the 5' ends of eukaryotic mRNAs, and new ones are being constantly identified. The m⁷G cap is recognized by several specialized proteins involved in mRNA transport, translation, translational repression and degradation. In eukaryotes, a crucial step in translation initiation is the binding of the translation initiation factor 4E (eIF4E) to the 5' end of the mRNA.¹ Through binding of the cap and interactions with other constituents of the translation initiation complex, eIF4E participates in the recruitment of the small ribosomal subunit onto mRNA. The 5' cap is also essential for mRNA stability. mRNA decapping by the Dcp1/2 complex is a prerequisite for the 5' → 3' decay pathway.^{2,3} Other cap-recognizing proteins and enzymes include the nuclear cap binding complex (CBC), the decapping

protein hNUDt16 or the RNA-independent decapping scavenger (DcpS).^{4–7} Interestingly, besides proteins, nucleic acids may also specifically recognize the cap. Histone H4 mRNA forms a pocket within the ORF region capable of sequestering its 5' cap, which contributes to an untypical translation initiation regulatory mechanism.⁸ Artificial RNA cap-targeting aptamers have been developed by an *in vitro* selection process (SELEX).⁹

Studying cap–protein and cap–nucleic acid interactions at the molecular level may be effectively supported by properly designed chemically modified cap analogs.¹⁰ One possible way of studying the interaction of RNAs with other species is through photo-crosslinking experiments, especially those facilitated by photo-reactive nucleosides. Here, we describe the synthesis and properties of new anti-reverse mRNA cap analogs (m₂^{7,2'-O}Gppp^{6S}G, **1** and m₂^{7,2'-O}Gppsp^{6S}G, **2**) bearing a photo-activable nucleoside, 6-thioguanosine (Fig. 1). The analogs have been rationally designed to make them reagents suitable for the preparation of capped RNAs by *in vitro* transcription. The presence of ^{6S}G as a second nucleoside makes them suitable for photo-induced crosslinking experiments, but also enables their incorporation into mRNA. The methyl group at the 2'-O position of 7-methylguanosine ensures only correctly oriented (forward) incorporation of the cap analogs into RNA (such analogs are referred to as anti-reverse cap analogs – ARCA).^{11,12} Cap analog **2** is additionally modified with a phosphorothioate group at the β-position of the triphosphate bridge to increase the stability and translational efficiency of mRNA (Fig. 1). We have previously shown that introduction of

^aDivision of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, Zwirki i Wigury 93, 02-089 Warsaw, Poland

^bArchitecture et Réactivité de l'ARN, Université de Strasbourg, CNRS, Institut de Biologie Moléculaire et Cellulaire, 15 rue René Descartes, 67084 Strasbourg Cedex, France

^cCentre of New Technologies, University of Warsaw, Zwirki i Wigury 93, 02-089 Warsaw, Poland. E-mail: jacekj@biogeo.uw.edu.pl; Fax: +48 22 55 40 771; Tel: +48 22 55 40 774

† Electronic supplementary information (ESI) available: Fig. S1–S3 and RP HPLC profiles, UV-VIS, HRMS and NMR spectra of compounds **1**, **2a** and **2b**. See DOI: 10.1039/c4ob00059e

‡ These authors contributed equally to this work.






Fig. 1 Structure of cap analogs containing 6-thioguanosine (**1** and **2**) synthesized and studied in this work and their use for obtaining capped-RNAs site-selectively labeled with ^{65}G within the cap structure. Cap analog **2**, which is additionally modified at the β position of the triphosphate bridge with a phosphorothioate group, exists as a mixture of two P-diastereomers designated D1 and D2 (**2a** and **2b**).

this modification into mRNA cap confers resistance to Dcp1/2 and stabilizes interaction with eIF4E, resulting in an increased translational efficiency and half-life of mRNA *in vivo*.^{13–15}

6-Thioguanosine (^{65}G) and other thionucleosides absorb light at wavelengths longer than 300 nm and, thus, can be selectively photoactivated in the presence of natural nucleic acids and proteins, which absorb UV light at shorter wavelengths.

Introduction of photoreactive nucleosides into DNA or RNA enables photo-crosslinking experiments directed at identification of protein–nucleic acid and nucleic acid–nucleic acid interactions or detailed mapping of binding sites.^{16–18} Furthermore, several chemical approaches have been developed to introduce ^{65}G into nucleic acids and subsequently derivatize at the S^6 -position, either directly or through functionality transfer reactions, which opens numerous possibilities for nucleic acid modification and labeling.^{19–24} The solution structures of DNA duplexes containing ^{65}G indicate that ^{65}G is generally capable of maintaining Watson–Crick interactions with cytosine and does not perturb duplex structure significantly.²⁵ However, the stability of the $^{65}\text{G}:\text{C}$ pair is lower compared to $\text{G}:\text{C}$, which results in decreased duplex stability and blocks formation of G-quadruplexes.^{26,27}


RNAs modified with ^{65}G at random positions within the RNA body can be obtained by performing transcription *in vitro* in the presence of a ^{65}GTP and GTP mixture.¹⁶ The cap analogs reported in this paper, on the other hand, enable

preparation of capped transcripts that are labeled with ^{65}G selectively at the position of the first transcribed nucleotide (Fig. 1). Such RNAs should be particularly useful for cross-linking experiments targeting 5' cap binding biomolecules. In order to evaluate the influence of the ^{65}G moiety on the biological properties of the cap, we studied the interaction of cap analogs **1**, **2a** and **2b** with eIF4E and determined the *in vitro* translation efficiencies for mRNAs capped with these compounds. In a model experiment we also demonstrated that histone H4 mRNAs capped with **1** efficiently undergo photo-crosslinking upon UV-A irradiation.

Results and discussion

Chemical synthesis

The synthesis of ^{65}G containing cap analogs was accomplished by employing phosphorimidazolide chemistry (Scheme 1). Since 6-thioguanosine turned out to be compatible with the standard phosphorylation, imidazole-activation and pyrophosphate bond formation procedures, the synthetic pathway was straightforward, starting directly from commercially available, unprotected 6-thioguanosine (Scheme 1). The 6-thioguanosine was treated with phosphorus oxychloride to produce 6-thioguanosine monophosphate **3**. The conversion of the nucleoside into 5'-phosphorylated product was almost quantitative as determined by reversed-phase HPLC. The aqueous work-up and purification by ion-exchange chromatography on DEAE Sephadex afforded **3** in an 86% yield. Compound **3** was converted into its P-imidazolide derivative **4** by employing a dithiodipyridine/triphenylphosphine activation system. Finally, **4** was coupled to either $N^7,2'$ -O-dimethylguanosine 5'-diphosphate (**5**)¹¹ or its β -phosphorothioate¹⁵ counterpart (**6**) to produce cap analogs **1** and **2**, respectively (Fig. 2). The efficiencies of coupling reactions between **4** and either **5** or **6** were comparable to analogous reactions with guanosine



Scheme 1 Synthesis of cap analogs **1** and **2** modified with the 6-thioguanosine (^{65}G) moiety.






Fig. 2 RP HPLC profiles from the synthesis of cap analog **1** (A) and a diastereomeric mixture of **2a** and **2b** (B).

5'-phosphorimidazolide.¹⁵ After purification the desired compounds could be isolated with good yields (48% and 54%, respectively) and on a reasonable scale (tens of milligrams). Upon formation of the pyrophosphate bond between **4** and **6**, a new stereogenic center at the β -phosphor atom of the triphosphate bridge is created. Consequently, compound **2** is isolated as a mixture of two P-diastereomers. The diastereomers separated during RP HPLC analysis and thus were designated D1 and D2 according to their elution order (compounds **2a** and **2b**, respectively; Fig. 2B).

The mixture of **2a** and **2b** could be resolved by semi-preparative reversed-phase HPLC and thus diastereomerically pure samples of **2a** and **2b** could be subjected to further studies.

Interaction with eIF4E and translational efficiency of capped mRNAs

The influence of a chemical modification on the biochemical properties of a given cap analog may be preliminarily assessed by determining its binding affinity for the cap-binding translation factor eIF4E and comparing the result to an unmodified ligand.

Such an assessment might be performed by fluorescence quenching titration, *i.e.* by titration of eIF4E with increasing amounts of the cap analog and measuring the quenching of protein tryptophan fluorescence (excitation at 280 nm and emission at 337 nm). In the case of cap analogs containing ^{6S}G as the second nucleoside, their absorption spectra overlap with eIF4E emission in the range 310–365 nm. In order to eliminate the effect of re-absorption of the light emitted by eIF4E by ^{6S}G cap analogs on the analysis, the changes of eIF4E fluorescence intensity were observed at 380 nm. The association constants K_{AS} for **1**, **2a** and **2b** derived from the titration curves are given in Table 1, together with the same data for previously reported structurally related compounds. Comparison of the data for ^{6S}G containing cap analogs with guanine parent compounds indicates that introduction of a ^{6S}G moiety, in general, slightly increases the binding affinity for eIF4E (by 1.3-fold to 1.6-fold).

Table 1 Biochemical properties of cap analogs containing the ^{6S}G moiety

Compound		K_{AS} cap-eIF4E [μM^{-1}]	Relative translation efficiency of capped mRNA ^a
No.	Abbreviation		
	m ⁷ GpppG	9.4 ± 0.4	1
	m ₂ ^{7,2'-O} GpppG	10.2 ± 0.4	1.68 ± 0.34 (n = 3)
1	m ₂ ^{7,2'-O} Gppp ^{6S} G	16.7 ± 0.8	0.45 ± 0.03 (n = 3)
2a	m ₂ ^{7,2'-O} Gppsp ^{6S} G (D1)	54.6 ± 3.1	0.60 ± 0.06 (n = 3)
2b	m ₂ ^{7,2'-O} Gppsp ^{6S} G (D2)	27.0 ± 0.3	0.68 ± 0.06 (n = 3)
	ApppG	n.d.	0.12 ± 0.03 (n = 3)
	m ₂ ^{7,2'-O} GppspG (D1)	42.1 ± 1.6	n.d.
	m ₂ ^{7,2'-O} GppspG (D2)	18.3 ± 3.4	1.91 ± 0.01 (n = 1)

^a n = number of experiments performed (on two independent sets of mRNA transcripts).

In agreement with previous results, introduction of the phosphorothioate moiety at the β -position of the triphosphate bridge has an additional stabilizing effect depending on the stereochemistry of the phosphorus center.¹⁵

Next, we tested the new cap analogs **1**, **2a** and **2b** as substrates for the preparation of mRNAs by a transcription *in vitro* reaction catalyzed by SP6 polymerase. All new 6-thioguanosine cap analogs are effectively incorporated into short RNA transcripts (6 nt) (ESI Fig. 1†). However, the intensity of UV-shadowed bands of the **1**, **2a** and **2b** capped transcripts was slightly reduced in comparison to control caps: m⁷GpppG and m₂^{7,2'-O}GppspG. Next, we transcribed full-length luciferase-encoding mRNAs capped with either **1**, **2a**, **2b**, m⁷GpppG or m₂^{7,2'-O}GppspG (D2). All transcripts were obtained with efficiencies indistinguishable from m⁷GpppG-capped RNA (ESI Fig. 2†). The translational efficiencies in rabbit reticulocyte lysate (RRL) were determined by adding various concentrations of mRNA to the lysate (which was beforehand optimized for cap-dependent translation) and measuring the luciferase activity after 60 min. Table 1 summarizes the average translation efficiencies from replicate experiments, calculated as the initial slopes of luciferase activity *versus* mRNA concentration, whereas plots from a representative experiment are depicted in ESI Fig. 3.† The determined translation efficiencies were normalized to the mRNA capped with m⁷GpppG, for which the translation efficiency was set to 1. The mRNA with a non-functional cap analog (ApppG) was used to estimate the level of cap-independent translation. Surprisingly, despite the high affinities of ^{6S}G-modified cap analogs to eIF4E, mRNAs capped with these compounds were translated with relatively low efficiencies in RRL. The translation efficiency for m₂^{7,2'-O}Gppp^{6S}G-mRNA was only 0.45 ± 0.01 compared to m⁷GpppG-mRNA. Both stereoisomers of m₂^{7,2'-O}Gppsp^{6S}G-mRNA were translated slightly more efficiently than m₂^{7,2'-O}Gppp^{6S}G-mRNA. This observation is in agreement with the previously described effect of β -phosphorothioate substitution, but it was not as pronounced as that for the corresponding analogs bearing unmodified guanosine. The D2 stereoisomer (**2b**) was the one conferring the highest trans-



lation efficiency to mRNA among the three analogs tested, which is also in agreement with previous findings.¹⁴ It should be noted, however, that even though the translation efficiency value for $m_2^{7,2'-O}\text{Gppp}^{65}\text{G}$ -mRNA was lower than expected, it was still threefold higher than the translation efficiency of mRNA capped with non-functional (AppppG-capped) mRNA. This indicates that the ^{65}G -modified RNAs to a significant extent remained translated in a cap-dependent manner.

Intrastrand cap-RNA crosslinking

Finally, to verify the utility of ^{65}G -labeled cap analogs for photo-induced crosslinking, we performed intrastrand crosslinking experiments on histone H4 mRNA capped with **1**.

Histone H4 mRNAs do not conform to the conventional translation initiation model, but undergo an unusual process, which might be considered as a hybrid mechanism between canonical and IRES-driven translation initiation.⁸ The ORF of the histone H4 mRNA contains two structural elements critical for translation initiation. The 5' proximal structure placing 19 nucleotides downstream of the initiation codon forms a three-way helix junction, which serves as an $m^7\text{G}$ Cap-Binding Pocket (CBP). The secondary structure of the CBP element is shown in Fig. 3A. Since the $m^7\text{G}$ cap is sequestered, it is not accessible to eIF4E. A second structural element, a 4E-Sensitive Element (4E-SE), internally recruits eIF4E without the need for the cap. Consequently, small ribosomal subunits become tethered directly on the AUG start codon without any scanning step. The 4E-SE facilitates direct positioning of the ribosome on the start codon.

Here, we used a UV crosslinking experiment combined with a primer extension assay on H4 mRNA capped with $m_2^{7,2'-O}\text{Gppp}^{65}\text{G}$ (**1**) to gain some insight into the spatial structure of the cap in the CBP. For comparison, we also used mRNA capped with 7-methyl-6-thioguanosine ($m^{7,65}\text{GpppG}$ -mRNA) obtained *via* enzymatic capping using ^{65}GTP as a substrate, as previously described.⁸ First, RNA was subjected to crosslinking using UV and, then, reverse transcription was performed. The covalent crosslink induces a reverse-transcription arrest (RT stop) that is positioned by running a sequencing reaction performed using the same primer. Fig. 3B and C show results of the crosslinking experiment followed by reverse-transcription of the crosslinked mRNA. Crosslinking experiments at 312 nm allow specific activation of a 6-thio moiety. Using the enzymatically obtained $m^{7,65}\text{GpppG}$ -RNA, we detected double RT stops at positions 40, 41 and triple RT stops at 105, 106 and 107 (Fig. 3B). These RT stops are located on both sides of the RNA helix and are specific since they are not observed in the absence of UV irradiation. Another experiment performed with $m_2^{7,2'-O}\text{Gppp}^{65}\text{G}$ -RNA shows that, indeed, cap analog **1** is very efficient for UV crosslinking; however, the RT stops have moved two nucleotides downstream onto position 42 and 43, whereas RT stops on 105, 106 and 107 are not observed. Hence, if the 6-thio moiety is moved in the cap, the crosslink appears at another place in the cap binding pocket. In order to precisely position the cap in CBP, we next performed crosslinking at 365 nm which induces so-




Fig. 3 UV-crosslinking experiments on histone H4 RNAs selectively modified with ^{65}G within the cap. $m_2^{7,2'-O}\text{Gppp}^{65}\text{G}$ -RNA was obtained by co-transcriptional capping with cap analog **1**, whereas $m^{7,65}\text{GpppG}$ -RNA was obtained by post-transcriptional capping with ^{65}GTP . (A) The secondary structure of the histone H4 mRNA cap-binding pocket. (B) and (C) Results of the crosslinking experiments at 312 and 365 nm followed by reverse-transcription of the crosslinked mRNA. (D) Crosslinking sites detectable after irradiation at different wavelengths (365 nm reveals so-called “zero-length” crosslinks). (E) Residues responsible for cap recognition identified by crosslinking.

called “zero-length” crosslinks.²⁸ At this wavelength, atoms have to be in a sphere of maximum 2 Å around the thio moiety to be able to create a covalent link. UV irradiation at 365 nm with $m^{7,65}\text{GpppG}$ -RNA resulted in the detection of the same RT stops at positions 40, 41, 105, 106 and 107 indicating that these residues are located in the close vicinity (max 2 Å) of the thio moiety of $m^7\text{G}$ (Fig. 3C). In contrast, UV irradiation at 365 nm with $m_2^{7,2'-O}\text{Gppp}^{65}\text{G}$ -RNA did not lead to any RT stops, which suggests that residues at positions 42 and 43 are located at a distance higher than 2 Å from the thio moiety of cap analog **1**. The positions of the RT stops induced by UV irradiation are summarized in Fig. 3D. In summary, by comparing the results of UV irradiation at 312 nm and 365 nm, we propose a topology model of the cap in the CBP that is shown in Fig. 3E.



Conclusions

In the present study, we demonstrated an efficient and straightforward synthesis of three dinucleotide mRNA cap analogs containing a 6-thioguanosine moiety. The new analogs are recognized by translation initiation factor 4E with a high affinity, are incorporated into mRNA transcripts by SP6 and T7 RNA polymerases and such transcripts undergo cap-dependent translation. We have also performed a UV-crosslinking experiment combined with a primer extension assay on histone H4 mRNA capped with a ^{65}G -modified cap analog. The experiment allowed for the mapping of a H4 mRNA cap-binding site, proving the new analogs to be useful tools in studies on cap-dependent processes.

Experimental

Chemical synthesis

General information. 6-Thioguanosine and all chemical and solvents were purchased from Sigma-Aldrich and used without any further treatment, unless otherwise stated. Intermediate nucleotides $m_2^{7,2'-\text{O}}\text{GDP}$ (**5**), $m_2^{7,2'-\text{O}}\text{GMP-Im}$ and $m_2^{7,2'-\text{O}}\text{GDP}\beta\text{S}$ (**6**) were synthesized as described previously.^{11,15,29} The synthesized nucleotides were purified by ion-exchange chromatography on a DEAE-Sephadex A-25 (HCO_3^- form) column. A column was loaded with the reaction mixture and washed thoroughly with water (until the eluate did not precipitate with AgNO_3 solution) to elute metal(II)/EDTA complexes. Then, the nucleotides were eluted using a linear gradient of triethylammonium bicarbonate (TEAB) in deionized water. Collected fractions were analyzed spectrophotometrically at 260 nm or 340 nm (for compounds with 6-thioguanosine) and fractions containing nucleotides or cap analogs were analyzed by reverse-phase HPLC and combined. After evaporating under reduced pressure with repeated addition of ethanol to decompose TEAB, compounds were isolated as triethylammonium (TEA) salt. Yields were calculated on the basis of either sample weight or optical density milliunits (mOD) of the product. Optical measurements for ^{65}G -nucleotides were performed in 0.1 M phosphate buffer pH = 7 at 340 nm (^{65}G absorption maximum) assuming $\epsilon_{340} = 24\,800\text{ cm}^{-1}\text{ M}^{-1}$ for calculations. For $m^7\text{G}$ -nucleotides, measurements were conducted in 0.1 M phosphate buffer pH = 6 at 260 nm, assuming $\epsilon_{260} = 11\,400\text{ cm}^{-1}\text{ M}^{-1}$.

Analytical RP HPLC was performed with an Agilent Tech. Series 1200 instrument using a Supelcosil LC-18-T HPLC column ($4.6 \times 250\text{ mm}$, flow rate 1.3 mL min^{-1}) with a 0–25% linear gradient of methanol in 0.05 M ammonium acetate buffer (pH 5.9) for 15 min and UV detection at 254 nm and 340 nm. Semi-preparative HPLC was performed on the same apparatus equipped with a Discovery Reverse-Phase Amide C-16 HPLC column ($25\text{ cm} \times 21.2\text{ mm}$, $5\ \mu\text{m}$, flow rate 5.0 mL min^{-1}) and UV detection at 254 nm and 340 nm. The purity and homogeneity of each final product were confirmed by RP HPLC, high resolution mass spectrometry HRMS (ES^-) and ^1H NMR and ^{31}P NMR spectroscopy. Mass spectra were recorded

with a high resolution LTQ Orbitrap Velos (Thermo Scientific). NMR spectra were recorded at 25 °C with a Varian UNITY-plus spectrometer at 399.94 MHz (^1H NMR) and 161.90 MHz (^{31}P NMR). ^1H NMR chemical shifts were calibrated to sodium 3-trimethylsilyl-[2,2,3,3- D_4]-propionate (TSP) in D_2O as an internal standard. ^{31}P NMR chemical shifts were reported to 20% phosphorus acid in D_2O as an external standard. The raw NMR files were processed using ACD/Labs 12.0 Software.

6-Thioguanosine 5'-O-monophosphate, triethylammonium salt (3). To a vigorously stirred suspension of 6-thioguanosine in trimethyl phosphate cooled to 0 °C, freshly distilled phosphorus oxychloride (782 μl , 7.78 mmol) was added. The reaction mixture was stirred at 0 °C and the reaction progress was monitored using RP HPLC (samples were prepared by 10 \times diluting a sample from the reaction mixture in 5% aqueous NaHCO_3). The reaction was quenched after 48 h by the addition of 5% aqueous NaHCO_3 solution. DEAE-Sephadex purification, performed according to general information (0–0.7 M TEAB), afforded **3** in a 68% yield (triethylammonium salt, 1.01 g, 52 500 mOD₃₄₀, 2.12 mmol). ^1H NMR δ_{H} (400 MHz; D_2O , TSP), 1.28 (18H, t, J 7.3), 3.20 (12H, q, J 7.2), 4.05–3.99 (3H, m), 4.32 (1H, d, J 3.1), 4.50 (1H, dd, J 3.1, 6.0), 5.94 (1H, d, J 6.0), 8.34 (1H, s), ^{31}P NMR δ_{P} (162 MHz; D_2O , H_3PO_4) 0.13 (1P, s), HPLC (reversed phase): $t_{\text{R}} = 4.7\text{ min}$, HRMS (ES^-): calcd for $\text{C}_{10}\text{H}_{13}\text{N}_5\text{O}_7\text{PS}$ [$\text{M} - \text{H}$] $^-$ 378.0274; found 378.0285.

6-Thioguanosine 5'-O-phosphorimidazolide, lithium salt (4). Compound **3** (1.01 g, 2.12 mmol, 52 530 mOD₃₄₀), imidazole (1.44 g, 21.18 mmol), and 2,2'-dithiodipyridine (1.40 g, 6.35 mmol) were mixed in 10 mL of DMF. Triethylamine (808 μl , 4.24 mmol) and triphenylphosphine (1.66 g, 6.35 mmol) were added, and the mixture was stirred for 6–8 h. The product was precipitated from a reaction mixture with anhydrous LiClO_4 (1.04 g, 8.47 mmol) solution in dry acetone (100 mL). After cooling at 4 °C, the precipitate was filtered, washed repeatedly with cold, dry acetone, and dried in a vacuum over P_4O_{10} to afford 903 mg of **4** (2.10 mmol, 52 350 mOD₃₄₀, 99%). ^1H NMR δ_{H} (500 MHz; D_2O , TSP), 4.10 (2H, m), 4.26 (1H, m), 4.43 (1H, dd, J 5.1, 4.2), 4.82 (1H, t, J 5.1), 5.85 (1H, d, J 5.1), 8.04 (1H, s), ^{31}P NMR δ_{P} (202.6 MHz; D_2O , H_3PO_4) -7.81 (1P, s), HPLC (reversed phase): $t_{\text{R}} = 9.8\text{ min}$, HRMS (ES^-): calcd for $\text{C}_{13}\text{H}_{15}\text{N}_7\text{O}_6\text{PS}$ [$\text{M} - \text{H}$] $^-$ 428.05476; found 428.05448.

***N*⁷,2'-O-dimethylguanosine P1-(6-thioguanosin-5'-yl)-P3-triphosphate, sodium salt (1).** $m_2^{7,2'-\text{O}}\text{GDP}$ (**5**) (52 mg, 0.11 mmol, 1247 mOD₂₆₀) was mixed with **4** (60 mg, 0.13 mmol, 3286 mOD₃₄₀) and the resulting mixture was suspended in 1.85 mL of DMF. Subsequently, anhydrous zinc chloride (179 mg, 1.33 mmol) was added and rapid dissolution of the reagents was observed. The reaction was quenched by the addition of a solution of NaHCO_3 (246 mg, 2.93 mmol) and EDTA (493 mg, 1.33 mmol) in 18.5 mL of water. Purification on a DEAE-Sephadex (0–1.2 M TEAB) afforded 44 mg (1300 mOD₃₄₀, 0.052 mmol, 48%) of **1** triethylammonium salt. After evaporating to dryness, the product was re-dissolved in 0.5 mL of water and precipitated with NaClO_4 (0.624 mmol) solution in acetone. The precipitate was centrifuged, washed



with acetone, dissolved in water and freeze dried to finally afford 36 mg (0.043 mmol, 40%) of **1**, trisodium salt. ^1H NMR δ_{H} (400 MHz; D_2O , TSP) 3.59 (3H, s), 4.04 (3H, s), 4.20 (1H, dd, J 2.7, 4.7), 4.43–4.22 (6H, m), 4.51–4.46 (2H, m), 4.70 (1H, dd, J 5.0, 6.2), 5.80 (1H, d, J 6.2), 5.94 (1H, d, J 2.7), 8.16 (1H, s), 8.91* (1H, s), ^{31}P NMR δ_{P} (162 MHz; D_2O , H_3PO_4) –22.26 (1P, t, J 19.1), –10.73 (2P, d, J 19.1), HPLC (reversed phase): $t_{\text{R}} = 7.0$ min, HRMS(ES^-): calcd For $\text{C}_{22}\text{H}_{29}\text{N}_{10}\text{O}_{17}\text{P}_3\text{S}$ [$\text{M} - \text{H}$] $^-$ 831.07294; found 831.07255. * D_2O exchangeable proton.

$\text{N}^7,2'$ -*O*-Dimethylguanosine P1-[6-thioguanosin-5'-yl-P3-(2-thiotriphosphate)] D1 and D2 ammonium salt (2a and 2b). $\text{m}_2^{7,2'\text{-O}}\text{GDP}\beta\text{S}$ (**6**) was synthesized according to previously reported procedures.^{15,29} Briefly, $\text{m}_2^{7,2'\text{-O}}\text{GMP-Im}$ (250 mg, 0.46 mmol, 5228 mOD₂₆₀) was mixed with triethylammonium thiophosphate (250 mg, 0.88 mmol) and the resulting mixture was suspended in 3.75 mL of DMF. Subsequently, anhydrous zinc chloride (621 mg, 4.59 mmol) was added and rapid dissolution of the reagents was observed under stirring. The reaction was quenched after 15 minutes by the addition of a solution of NaHCO_3 (853 mg, 10.16 mmol) and EDTA (1.71 g, 4.59 mmol) in 38 mL of water. Purification on a DEAE-Sephadex (0–0.9 M TEAB) afforded 192 mg of $\text{m}_2^{7,2'\text{-O}}\text{GDP}\beta\text{S}$ (0.28 mmol, 3184 mOD₂₆₀, 61%), which was immediately used in the following reaction. $\text{m}_2^{7,2'\text{-O}}\text{GDP}\beta\text{S}$ (192 mg, 0.28 mmol, 3184 mOD₂₆₀) was mixed with $^{65}\text{GMP-Im}$ (169 mg, 0.37 mmol, 9176 mOD₃₄₀) and the resulting mixture was suspended in 3.75 mL of DMF. Subsequently, anhydrous zinc chloride (378 mg, 2.79 mmol) was added and rapid dissolution of the reagents was observed. The reaction was quenched by the addition of a solution of NaHCO_3 (520 mg, 6.18 mmol) and EDTA (1.04 g, 2.79 mmol) in 38 mL of water. Purification on a DEAE-Sephadex (0–1.2 M TEAB) afforded 127 mg of a diastereomeric mixture of $\text{m}_2^{7,2'\text{-O}}\text{Gppp}^{65}\text{G}$ D1 and D2 (triethylammonium salt, 0.15 mmol, 3726 mOD₃₄₀, 54%). Separation of the diastereomers on semi-preparative HPLC afforded 59 mg of $\text{m}_2^{7,2'\text{-O}}\text{Gppp}^{65}\text{G}$ D1 (**2a**) and 28 mg of $\text{m}_2^{7,2'\text{-O}}\text{Gppp}^{65}\text{G}$ D2 (**2b**). **2a**: ^1H NMR δ_{H} (400 MHz; D_2O , TSP) 3.61 (3H, s), 4.09–4.03 (3H, m), 4.48–4.24 (7H, m), 4.59–4.53 (2H, m), 4.75 (1H, dd, J 5.3, 6.2), 5.83 (1H, d, J 6.2), 6.00 (1H, d, J 2.5), 8.19 (1H, s), 9.03 (1H, s)*, ^{31}P NMR δ_{P} (162 MHz; D_2O , H_3PO_4) –11.56 (2P, d, J 25.5), 30.82 (1P, t, J 25.5), **2b**: ^1H NMR δ_{H} (400 MHz; D_2O , TSP) 3.59 (3H, s), 4.07 (3H, s), 4.46–4.21 (7H, m), 4.52 (1H, dd, J 3.2, 5.0), 4.55 (1H, dd, J 5.5, 5.7), 4.74 (1H, dd, J 5.5, 6.2), 5.81 (1H, d, J 6.2), 5.96 (1H, d, J 3.0), 8.17 (1H, s), 9.02 (1H, s)*, ^{31}P NMR δ_{P} (162 MHz; D_2O , H_3PO_4) –11.57 (2P, d, J 25.0), 30.72 (1P, t, J 25.0), HPLC (reverse phase): $t_{\text{R(D1)}} = 8.2$ min, $t_{\text{R(D2)}} = 8.3$ min, HRMS (ES^-): calcd for $\text{C}_{22}\text{H}_{29}\text{N}_{10}\text{O}_{16}\text{P}_3\text{S}_2$ [$\text{M} - \text{H}$] $^-$ 847.05010; found 847.04834 (for D1) and 847.04656 (for D2). * D_2O exchangeable proton.

Biophysical and biological experiments

Binding affinities for eIF4E. Fluorescence titration measurements were performed on an LS-55 spectrofluorometer (Perkin Elmer Co.) in 50 mM HEPES/KOH (pH 7.2), 100 mM KCl, 0.5 mM EDTA, 1 mM DTT at 20.0 ± 0.3 °C. Aliquots of 1 μl increasing concentrations of cap analog solutions were added

to 1.4 mL of 0.1 μM mouse eIF4E^(28–217) protein solutions, which were prepared as described previously.³⁰ Fluorescence intensities (excitation at 280 nm with 2.5 nm bandwidth and detection at 380 nm with 4 nm bandwidth and 290 nm cut-off filter) were corrected taking into account sample dilution and the *inner filter* effect. Equilibrium association constants (K_{AS}) were determined by fitting the theoretical dependence of the fluorescence intensity on the total concentration of the cap analog to the experimental data points according to the equation described previously.³¹ The final K_{AS} was calculated as the weighted average of three independent titration assays. Numerical nonlinear least-squares regression analysis was performed using ORIGIN 6.0 (Microcal Software Inc., USA).

In vitro transcription of luciferase mRNAs. Capped and polyadenylated luciferase mRNA transcripts were synthesized *in vitro* using SP6 RNA polymerase and the dsDNA template as described elsewhere.³² RNA transcripts, after the removal of the DNA template with RQ1 DNase (Promega), were purified with NucAway Spin Columns (Ambion) and analysed on a non-denaturing 1% agarose gel and their concentrations were determined spectrophotometrically.

Translation efficiency in vitro. The translation efficiency of differentially capped luciferase transcripts was determined in Flexi Rabbit Reticulocyte Lysate (RRL, Promega) as described previously.³² Briefly, the translation reactions were performed in 10 μl volume for 60 minutes at 30 °C under the conditions determined for cap-dependent translation (reaction mixtures were preincubated for 60 minutes at 30 °C before mRNA addition). A typical reaction contained: 40% RRL lysate (with 3.2 mM endogenous Mg^{2+} concentration), a mixture of amino acids (0.01 mM), MgCl_2 (0.6 mM), potassium acetate (210 mM) and 5'-capped luciferase mRNA transcript. Four different concentrations of each analyzed transcript were tested.

The activity of the synthesized luciferase was measured in a luminometer (Glomax, Promega), and depicted as a function of the capped luciferase mRNA concentration. After linear fitting to the obtained data points (OriginPro8 software), the translation efficiency of the tested transcripts was determined relative to the m^7GpppG -capped luciferase mRNA (the fitted line slope set to 1).

Synthesis of histone H4 mRNA and UV-crosslinking experiments. The $\text{m}^{7,65}\text{GpppG-H4}$ mRNA transcript was synthesized *in vitro* using T7 RNA polymerase run-off transcription, as previously described.⁸ $\text{m}_2^{7,2'\text{-O}}\text{Gppp}^{65}\text{G-RNA-H4}$ mRNA transcripts were synthesized by incorporating cap analog **1** during T7 RNA polymerase transcription. Both RNAs were irradiated with 312 and 365 nm for 30 min using a Bio-Link BLX 312 on ice. Cross-links were detected by primer extension using ^{32}P -labelled H4-specific primers and positioned by reverse sequencing using the same primers.

Acknowledgements

The authors are grateful to the Laboratory of Biological NMR (Institute of Biochemistry and Biophysics of the Polish



Academy of Sciences, IBB PAS) for access to their NMR apparatus, and Jacek Oledzki from the Laboratory of Mass Spectrometry (IBB PAS) for recording HRMS spectra. Financial support from the National Science Centre (Poland, UMO/2012/05/E/ST5/03893 to JJ and UMO-2013/08/A/NZ1/00866 to ED) and Agence Nationale pour le Recherche (France, ANR-2011-svse8 02501 to FM and AO) is gratefully acknowledged.

Notes and references

- 1 R. E. Rhoads, *J. Biol. Chem.*, 2009, **284**, 16711–16715.
- 2 Z. R. Wang, X. F. Jiao, A. Carr-Schmid and M. Kiledjian, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 12663–12668.
- 3 J. Coller and R. Parker, *Annu. Rev. Biochem.*, 2004, **73**, 861–890.
- 4 R. Worch, A. Niedzwiecka, J. Stepinski, C. Mazza, M. Jankowska-Anyszka, E. Darzynkiewicz, S. Cusack and R. Stolarski, *RNA*, 2005, **11**, 1355–1363.
- 5 G. Lu, J. Zhang, Y. Li, Z. Li, N. Zhang, X. Xu, T. Wang, Z. Guan, G. Gao and J. Yan, *Protein Cell*, 2011, **2**, 64–73.
- 6 M. G. Gu, C. Fabrega, S. W. Liu, H. D. Liu, M. Kiledjian and C. D. Lima, *Mol. Cell*, 2004, **14**, 67–80.
- 7 S. W. Liu, X. F. Jiao, H. D. Liu, M. G. Gu, C. D. Lima and M. Kiledjian, *RNA*, 2004, **10**, 1412–1422.
- 8 F. Martin, S. Barends, S. Jaeger, L. Schaeffer, L. Prongidi-Fix and G. Eriani, *Mol. Cell*, 2011, **41**, 197–209.
- 9 A. A. Haller and P. Sarnow, *Proc. Natl. Acad. Sci. U. S. A.*, 1997, **94**, 8521–8526.
- 10 J. Jemielity, J. Kowalska, A. M. Rydzik and E. Darzynkiewicz, *New J. Chem.*, 2010, **34**, 829–844.
- 11 J. Jemielity, T. Fowler, J. Zuberek, J. Stepinski, M. Lewdorowicz, A. Niedzwiecka, R. Stolarski, E. Darzynkiewicz and R. E. Rhoads, *RNA*, 2003, **9**, 1108–1122.
- 12 E. Grudzien-Nogalska, J. Stepinski, J. Jemielity, J. Zuberek, R. Stolarski, R. E. Rhoads and E. Darzynkiewicz, *Methods Enzymol.*, 2007, **431**, 203–227.
- 13 A. N. Kuhn, M. Diken, S. Kreiter, A. Selmi, J. Kowalska, J. Jemielity, E. Darzynkiewicz, C. Huber, O. Tureci and U. Sahin, *Gene Ther.*, 2010, **17**, 961–971.
- 14 E. Grudzien-Nogalska, J. Jemielity, J. Kowalska, E. Darzynkiewicz and R. E. Rhoads, *RNA*, 2007, **13**, 1745–1755.
- 15 J. Kowalska, M. Lewdorowicz, J. Zuberek, E. Grudzien-Nogalska, E. Bojarska, J. Stepinski, R. E. Rhoads, E. Darzynkiewicz, R. E. Davis and J. Jemielity, *RNA*, 2008, **14**, 1119–1131.
- 16 P. V. Sergiev, I. N. Lavrik, V. A. Wlasoff, S. S. Dokudovskaya, O. A. Dontsova, A. A. Bogdanov and R. Brimacombe, *RNA*, 1997, **3**, 464–475.
- 17 Z. Wang and T. M. Rana, *Biochemistry*, 1998, **37**, 4235–4243.
- 18 M. Ascano, M. Hafner, P. Cekan, S. Gerstberger and T. Tuschl, *Wiley Interdiscip. Rev.: RNA*, 2012, **3**, 159–177.
- 19 Y.-Z. Xu, *Bioorg. Med. Chem. Lett.*, 1998, **8**, 1839–1844.
- 20 Q. Zheng, Y. Wang and E. Lattmann, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 3141–3144.
- 21 Q. Zheng, Y. Wang and E. Lattmann, *Tetrahedron*, 2003, **59**, 1925–1932.
- 22 K. Onizuka, A. Shibata, Y. Taniguchi and S. Sasaki, *Chem. Commun.*, 2011, **47**, 5004–5006.
- 23 K. Onizuka, Y. Taniguchi and S. Sasaki, *Nucleosides Nucleotides Nucleic Acids*, 2009, **28**, 752–760.
- 24 S. Sasaki, K. Onizuka and Y. Taniguchi, *Chem. Soc. Rev.*, 2011, **40**, 5698–5706.
- 25 J. Bohon and C. R. de los Santos, *Nucleic Acids Res.*, 2003, **31**, 1331–1338.
- 26 J. Bohon and C. R. de los Santos, *Nucleic Acids Res.*, 2005, **33**, 2880–2886.
- 27 V. M. Marathias, M. J. Sawicki and P. H. Bolton, *Nucleic Acids Res.*, 1999, **27**, 2860–2867.
- 28 M. J. Moore and C. C. Query, *RNA-protein interactions: a practical approach*, IRL Press, Oxford, United Kingdom, 1998, pp. 75–108.
- 29 J. Kowalska, M. Lewdorowicz, E. Darzynkiewicz and J. Jemielity, *Tetrahedron Lett.*, 2007, **48**, 5475–5479.
- 30 J. Zuberek, A. Wyslouch-Cieszynska, A. Niedzwiecka, M. Dadlez, J. Stepinski, W. Augustyniak, A.-C. Gingras, Z. Zhang, S. K. Burley, N. Sonenberg, R. Stolarski and E. Darzynkiewicz, *RNA*, 2003, **9**, 52–61.
- 31 A. Niedzwiecka, J. Marcotrigiano, J. Stepinski, M. Jankowska-Anyszka, A. Wyslouch-Cieszynska, M. Dadlez, A. C. Gingras, P. Mak, E. Darzynkiewicz, N. Sonenberg, S. K. Burley and R. Stolarski, *J. Mol. Biol.*, 2002, **319**, 615–635.
- 32 A. M. Rydzik, M. Lukaszewicz, J. Zuberek, J. Kowalska, Z. M. Darzynkiewicz, E. Darzynkiewicz and J. Jemielity, *Org. Biomol. Chem.*, 2009, **7**, 4763–4776.

